menu
    • menu
    [{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sarah Cannon Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"O-(3,5-Dichlorophenyl)hydroxylamine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Sarah Cannon Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Sarah Cannon Research Institute"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"O-(3,5-Dichlorophenyl)hydroxylamine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for O-(3,5-Dichlorophenyl)hydroxylamine

    Menu

    O-(3,5-Dichlorophenyl)hydroxylamine

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Daiichi Sankyo

    Japan arrow
    AAN
    Not Confirmed

    Daiichi Sankyo

    Japan arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : O-(3,5-Dichlorophenyl)hydroxylamine

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

    Details : DS-7300,s an investigational B7-H3 directed ADC is comprised of a humanized anti-B7-H3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptidebased cleavable linkers.

    Product Name : DS-7300

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    July 20, 2022

    Lead Product(s) : O-(3,5-Dichlorophenyl)hydroxylamine

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Daiichi Sankyo

    Japan arrow
    AAN
    Not Confirmed

    Daiichi Sankyo

    Japan arrow
    AAN
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : O-(3,5-Dichlorophenyl)hydroxylamine

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Sarah Cannon Research Institute

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers

    Details : DS-7300, a B7-H3 directed DXd antibody drug conjugate (ADC) showed promising early clinical activity in patients with several types of advanced solid tumors that are refractory or intolerable to standard treatment or for whom no standard treatment exists...

    Product Name : DS-7300

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    September 17, 2021

    Lead Product(s) : O-(3,5-Dichlorophenyl)hydroxylamine

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Sarah Cannon Research Institute

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth